Literature DB >> 7680275

Simultaneous chronic lymphocytic leukemia and chronic myelogenous leukemia. Evidence of a separate stem cell origin.

V E Maher1, L Gill, P L Townes, J E Wallace, L Savas, B A Woda, J E Ansell.   

Abstract

The authors studied a patient with the simultaneous occurrence of chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML). The coexistence of these two hematologic malignancies leads to questions about their cell of origin. Through analysis of this patient's DNA, the authors studied the derivation of the two malignancies. They separated the blood into a myeloid-rich fraction and a fraction containing the malignant lymphocytes. JH and bcr probes were used to study these loci in the myeloid and lymphoid fractions and in unfractionated white blood cells. The authors found that the unfractionated leukocytes contained the bcr and JH rearrangements. Conversely, the lymphoid fraction contained only the JH rearrangement, and the myeloid fraction contained only the bcr rearrangement, suggesting that these malignancies arose from separate stem cells. This is the first reported patient with simultaneously occurring CML and CLL definitively shown to arise from distinct progenitors, and this report raises questions about the origin of these two cell lines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680275     DOI: 10.1002/1097-0142(19930315)71:6<1993::aid-cncr2820710612>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Risk of myelogenous leukaemia and multiple myeloma in workers exposed to benzene.

Authors:  D A Savitz; K W Andrews
Journal:  Occup Environ Med       Date:  1996-05       Impact factor: 4.402

2.  Risk of acute myeloid leukaemia and multiple myeloma in workers exposed to benzene.

Authors:  O Wong
Journal:  Occup Environ Med       Date:  1995-06       Impact factor: 4.402

3.  Chronic myeloid leukemia as a secondary malignancy following treatment of diffuse large B-cell lymphoma.

Authors:  Itır Şirinoğlu Demiriz; Emre Tekgündüz; Sinem Civriz Bozdağ; Fevzi Altuntaş
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.